How do we expedite the drug approval process in the United States? Co-Founder & CEO of EVQLV, Andrew Satz, educates us on how and what is needed to do so. 

To find out more about Andrew, please find him on LinkedIn here: https://www.linkedin.com/in/andrewsatz/

To find out more about EVQLV, please find the company website here: https://evqlv.com/

Key takeaways:

1. The acceleration of getting drugs to patients by decreasing costs for researchers, industry, and other key stakeholders motivates EVQLV.

2. A.I. will cause hyper-specialization, which will make doctors become more productive. 

3. Making data more accessible through government agencies and investing at a governmental level will drive future A.I.  models and specialized medicines for populations.